Wellness Wire Kansas: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Wellness Wire Kansas.

Press releases published on October 7, 2026

Oct. 7, 2026

Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants

Indeterminate GlobeNewswire

Oct. 7, 2026

Atsena Presents Positive Preliminary Safety and Efficacy Results from Parts A and B of the Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis

Indeterminate GlobeNewswire

Oct. 7, 2026

Cerevance Announces Positive Phase 3 ARISE Results: Once-daily Oral Solengepras Meets Primary Endpoint and Demonstrates Motor and Non-motor Benefits in Parkinson's Disease

Indeterminate GlobeNewswire

Oct. 7, 2026

Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum

Indeterminate GlobeNewswire

Oct. 7, 2026

BrewDog Rallies Beer Lovers Across the UK to Choose Craft

Indeterminate GlobeNewswire

Oct. 7, 2026

Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes

Indeterminate GlobeNewswire

Oct. 7, 2026

CHARM Therapeutics announces first patient dosed and first cohort fully enrolled in its Phase I/II clinical trial of CHM-029 for Acute Myeloid Leukemia

Indeterminate GlobeNewswire

Oct. 7, 2026

OrthoPediatrics Expands Its Lower Extremity Bracing Portfolio with the Launch of OPSB® Knee 'TractorFIX

Indeterminate GlobeNewswire

Oct. 7, 2026

Kane Biotech to Present Clinical Data and Showcase revyve® Product Line at SAWC Fall 2026

Indeterminate GlobeNewswire

Oct. 7, 2026

Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026

Indeterminate GlobeNewswire

Oct. 7, 2026

VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy

Indeterminate GlobeNewswire

Oct. 7, 2026

Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics

Indeterminate GlobeNewswire

Oct. 7, 2026

Matchpoint Therapeutics Announces $150 Million Series B Financing to Advance Pipeline of First-In-Class Oral Small Molecules for Autoimmune and Inflammatory Diseases

Indeterminate GlobeNewswire

Oct. 7, 2026

Atavistik Bio to Present at the Cure HHT 16th International Scientific Conference

Indeterminate GlobeNewswire

Oct. 7, 2026

Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease

Indeterminate GlobeNewswire

Oct. 7, 2026

BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

Indeterminate GlobeNewswire

Oct. 7, 2026

Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2

Indeterminate GlobeNewswire

Oct. 7, 2026

Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium

Indeterminate GlobeNewswire

Oct. 7, 2026

Teladoc Health Expands Solo Connected Care Platform with AI-Powered Capabilities to Help Hospitals Scale Smarter Care Delivery

Indeterminate GlobeNewswire

Oct. 7, 2026

New study finds a majority of younger men spend an unhealthy amount of time on social media, significantly impacting their mental health

Indeterminate GlobeNewswire